Unknown PHASE3 INTERVENTIONAL 1-arm NCT01570049

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma

Sponsor: Shandong Lanjin Pharmaceuticals Co.,Ltd

Conditions Non-Hodgkin Lymphoma by Clinical Course

Updated 6 times since 2017 Last updated: Aug 1, 2012 Started: Apr 30, 2010 Primary completion: Sep 30, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01570049, this PHASE3 trial focuses on Non-Hodgkin Lymphoma by Clinical Course and remains ongoing. Sponsored by Shandong Lanjin Pharmaceuticals Co.,Ltd, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong Lanjin Pharmaceuticals Co.,Ltd

Data source: Shandong Lanjin Pharmaceuticals Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China